Zoetis Inc. — Q1 2024 Form 10-Q
Business context and reporting period
Global animal-health company reporting the three months ended March 31, 2024, compared with Q1 2023. Zoetis operates U.S. and International segments and sells medicines, vaccines, diagnostics and related products across companion-animal and livestock markets.
Financial performance and liquidity
- Revenue: $2.190 billion, up 10% reported and 12% operational (excluding foreign exchange). Price contributed about 7%; new products about 4%; key dermatology products about 3%, partly offset by a 2% decline in other in-line products.
- Profit and EPS: Net income attributable to Zoetis was $599 million, up 9%; diluted GAAP EPS was $1.31, up 10%. Adjusted net income was $634 million, up 4%, and adjusted diluted EPS was $1.38, up 5% (both non-GAAP).
- Margins and costs: Cost of sales was 29.4% of revenue, unchanged year over year. U.S. segment gross margin rose to 81.3% from 79.8%; International segment gross margin declined to 68.9% from 70.2%. R&D expense increased 14% to $162 million.
- Cash flow: Operating cash flow was $595 million versus $549 million. Capital expenditures were $140 million versus $223 million. Cash and cash equivalents declined $66 million in the quarter to $1.975 billion.
- Debt and liquidity: Long-term debt was $6.562 billion and short-term borrowings were $24 million at March 31. Working capital was $4.450 billion; the current ratio was 3.33:1. The $1.0 billion revolving facility was undrawn, and the company reported compliance with its financial covenants.
- Capital returns: Zoetis repurchased 1.8 million shares for $339 million and paid $198 million in dividends. The declared quarterly dividend was $0.432 per share; $1.2 billion remained under the $3.5 billion repurchase authorization.
Material changes versus Q1 2023
- Companion-animal revenue increased 18% to $1.450 billion, while livestock revenue declined 5% to $720 million. U.S. revenue grew 16%; International revenue rose 3% reported and 8% operational, with foreign exchange reducing International growth by 5%.
- Growth included Simparica Trio, dermatology products and the osteoarthritis-pain monoclonal antibodies Librela and Solensia. U.S. livestock sales declined; International livestock growth was modest and varied by species and market.
- GAAP net income growth was supported by higher revenue and lower restructuring charges, but comparisons included $34 million of prior-year royalty-related income in Q1 2023. Other income, net, was $8 million in Q1 2024 versus $53 million in Q1 2023.
- Cash flow from operations improved partly because the prior-year period had a larger inventory build. Financing cash outflow was lower than in 2023, when Zoetis repaid $1.35 billion of notes at maturity.
Outlook, commentary, risks and unusual items
- Management stated that cash on hand, operating cash flows and financing arrangements should support cash needs for the next 12 months and beyond, while noting this depends on the operating environment. The supplied filing text does not provide a clear numerical full-year revenue or earnings guidance range.
- On April 28, 2024, after quarter-end, Zoetis announced an agreement to sell its medicated feed additive portfolio, certain water-soluble products and related assets to Phibro Animal Health for $350 million, subject to customary closing adjustments; completion was expected in the second half of 2024.
- Risks discussed include foreign-exchange movements, macroeconomic and geopolitical uncertainty, disease outbreaks, competition and generic entry, product safety or supply issues, regulation, R&D execution, litigation, and cyber and intellectual-property risks. About 43% of Q1 revenue was denominated in foreign currencies; FX reduced reported revenue growth by about 2%.
- Legal and environmental contingencies remain subject to uncertainty. The company believes they will not materially affect its financial position, but says results or cash flows in a period could be materially affected; it cannot estimate reasonably possible losses above accrued amounts. Net uncertain-tax-position liabilities were $212 million, plus $29 million of related interest and penalties.
Important facts for investors to verify
- Whether companion-animal product momentum, particularly Librela, Solensia and dermatology, continues to offset weakness in livestock and foreign-exchange headwinds.
- The closing, final proceeds and financial effects of the announced $350 million product-portfolio sale.
- Debt refinancing and repayment plans for $1.35 billion of principal due in 2025, alongside continued share repurchases and dividends.
- Developments in legal, environmental and tax contingencies, and any changes to management’s liquidity assessment or outlook.